A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIXTM in healthy children

被引：44

作者：

Lau, YL

Vessey, SJR

Chan, ISF

Lee, TL

Huang, LM

Lee, CY

Lin, TY

Lee, BW

Kwan, K

Kasim, SM

Chan, CY

Kaplan, KM

Distefano, DJ

Harmon, AL

Golie, A

Hartzel, J

Xu, J

Li, S

Matthews, H

Sadoff, JC

Shaw, A

机构：

[1] Merck & Co Inc, West Point, PA 19486 USA

[2] Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China

[3] Natl Taiwan Univ Hosp, Taipei, Taiwan

[4] Chung Gung Childrens Hosp, Taipei, Taiwan

[5] Natl Univ Singapore Hosp, Singapore 117548, Singapore

[6] Klin Kanak Kanak Kwan, Selangor, Malaysia

[7] Inst Pediat, Kuala Lumpur, Malaysia

来源：

VACCINE | 2002年 / 20卷 / 23-24期

关键词：

varicella zoster virus; immunogenicity; varicella vaccination;

D O I：

10.1016/S0264-410X(02)00245-1

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

This study compared safety, tolerability, and immunogenicity of the Oka/Merck varicella vaccine and VARILRIX(TM) [Oka-RIT strain SmithKline Beecham Biologicals] in healthy children 12-24 months of age. Subjects were randomized in this double blind study to receive either a single dose of Oka/Merck varicella vaccine, (similar to50,000 plaque forming units (PFU), Group A or similar to16,000 PFU, Group B) or 1 dose of VARILRIX(TM), (similar to40,000 PFU/dose, Group C). Safety profiles in each treatment group were similar. The proportions of subjects achieving a 6-week postvaccination titer greater than or equal to5 gpELISA units in Groups A, B or C were 97.1, 95.2 and 85.6%, respectively. (C) 2002 Elsevier Science Ltd. All rights reserved.

引用

页码：2942 / 2949

页数：8

共 22 条

[1]

ANDRE FE, 1985, POSTGRAD MED J, V61, P113

[2] CELL-MEDIATED-IMMUNITY TO VARICELLA-ZOSTER VIRUS [J].